ALX Oncology | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.41, missing the estimate of USD -0.3725.

EBIT: As of FY2025 Q3, the actual value is USD -22.93 M.

Research and Development Expenses: $17.4 million for the three months ended September 30, 2025, compared to $26.5 million for the same period in 2024. For the nine months ended September 30, 2025, R&D expenses were $59.4 million, compared to $92.8 million for the same period in 2024.
General and Administrative Expenses: $5.1 million for the three months ended September 30, 2025, compared to $6.1 million for the same period in 2024. For the nine months ended September 30, 2025, G&A expenses were $18.5 million, compared to $19.0 million for the same period in 2024.
Impairment Charge: $3.2 million for the nine months ended September 30, 2025, with no impairment charge for the same period in 2024.

Net Loss: $22.1 million for the three months ended September 30, 2025, compared to $30.7 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was $78.8 million, compared to $105.7 million for the same period in 2024.
Loss from Operations: $22.5 million for the three months ended September 30, 2025, compared to $32.6 million for the same period in 2024. For the nine months ended September 30, 2025, loss from operations was $81.0 million, compared to $111.9 million for the same period in 2024.

Net Cash Used in Operating Activities: $65.2 million for the nine months ended September 30, 2025, compared to $89.9 million for the same period in 2024.
Net Cash Provided by Investing Activities: $71.4 million for the nine months ended September 30, 2025, compared to $53.1 million for the same period in 2024.
Net Cash Used in Financing Activities: $0.3 million for the nine months ended September 30, 2025, compared to net cash provided by financing activities of $30.5 million for the same period in 2024.

Stock-Based Compensation Expense: $2.5 million for the three months ended September 30, 2025, compared to $7.0 million for the same period in 2024. For the nine months ended September 30, 2025, stock-based compensation expense was $9.9 million, compared to $21.2 million for the same period in 2024.

Core Business Focus: The company plans to continue advancing the clinical development of evorpacept and the initiation and advancement of clinical trials of ALX2004. The company expects to incur significant expenses and increasing operating losses for the foreseeable future as it continues to invest in research and development activities related to its existing product candidates.
Non-Core Business: The company may seek to enter into collaborations, licenses, and other similar arrangements for the development or commercialization of its product candidates. The company may also consider exploring development partnerships to advance its programs in gastric cancer.
Priority: The company aims to maintain its focus on the development and commercialization of its product candidates, with a particular emphasis on achieving regulatory approval and market acceptance for evorpacept and ALX2004.